Patrick O’brien Sells 15,000 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) COO Patrick O’brien sold 15,000 shares of the business’s stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $37.39, for a total value of $560,850.00. Following the transaction, the chief operating officer now directly owns 413,375 shares of the company’s stock, valued at $15,456,091.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Patrick O’brien also recently made the following trade(s):

• On Tuesday, January 3rd, Patrick O’brien sold 17,500 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $38.33, for a total value of $670,775.00.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $37.38 on Friday. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $26.81 and a fifty-two week high of $62.25. The company has a market capitalization of $3.96 billion, a P/E ratio of -22.25 and a beta of 1.26. The stock has a 50-day simple moving average of $33.74 and a 200-day simple moving average of $36.65.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last posted its earnings results on Monday, November 28th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.24). The firm had revenue of $31.58 million during the quarter, compared to analysts’ expectations of $107.60 million. Arrowhead Pharmaceuticals had a negative net margin of 71.01% and a negative return on equity of 40.23%. As a group, analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -0.69 earnings per share for the current year.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Captrust Financial Advisors raised its stake in Arrowhead Pharmaceuticals by 22.4% during the 2nd quarter. Captrust Financial Advisors now owns 1,201 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 220 shares during the last quarter. Arizona State Retirement System raised its stake in Arrowhead Pharmaceuticals by 1.2% during the 2nd quarter. Arizona State Retirement System now owns 27,151 shares of the biotechnology company’s stock valued at $956,000 after acquiring an additional 309 shares during the last quarter. Private Advisor Group LLC raised its stake in Arrowhead Pharmaceuticals by 2.7% during the 3rd quarter. Private Advisor Group LLC now owns 11,795 shares of the biotechnology company’s stock valued at $390,000 after acquiring an additional 313 shares during the last quarter. O Shaughnessy Asset Management LLC increased its position in Arrowhead Pharmaceuticals by 3.5% during the 2nd quarter. O Shaughnessy Asset Management LLC now owns 9,704 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 326 shares during the period. Finally, State of Alaska Department of Revenue increased its position in Arrowhead Pharmaceuticals by 2.2% during the 2nd quarter. State of Alaska Department of Revenue now owns 15,173 shares of the biotechnology company’s stock worth $534,000 after purchasing an additional 330 shares during the period. 65.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ARWR shares. SVB Leerink decreased their price target on Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a “market perform” rating for the company in a report on Tuesday, November 29th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $66.00 price target (up from $65.00) on shares of Arrowhead Pharmaceuticals in a report on Wednesday, November 30th. StockNews.com started coverage on Arrowhead Pharmaceuticals in a report on Wednesday, October 12th. They set a “hold” rating for the company. Morgan Stanley decreased their price target on Arrowhead Pharmaceuticals from $41.00 to $37.00 and set an “equal weight” rating for the company in a report on Tuesday, November 29th. Finally, Piper Sandler decreased their price target on Arrowhead Pharmaceuticals from $72.00 to $64.00 and set an “overweight” rating for the company in a report on Wednesday, November 9th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $62.67.

About Arrowhead Pharmaceuticals

(Get Rating)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis.